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Supplementary Figures 
 
 
Supplementary Figure 1 | Rim15 ensures Sic1 accumulation following TORC1 inactivation independently 
of the yeast strain background. The levels of endogenous Sic1, in exponentially growing (0 h) and rapamycin-
treated (RAP; 1-4 h) BY4741, W303-1A, and SP1 wild-type (WT) and respective isogenic rim15∆ mutant cells, 
were determined by immunoblot analyses using polyclonal anti-Sic1 antibodies. Adh1 levels served as loading 
controls. 
 
 
 
Supplementary Figure 2 | Mutation of Thr
173
 to Ala in Sic1, like loss of Rim15, compromises normal Sic1 
accumulation in rapamycin-treated cells. Sic1 levels and phosphorylation of Thr
173
 in Sic1 (Sic1-pThr
173
) 
were determined in exponentially growing (0 h) and rapamycin-treated (RAP; 2 and 4 h) cells with the indicated 
genotypes by immunoblot analyses using polyclonal anti-Sic1 and phosphospecific anti-Sic1-pThr
173
 antibodies, 
respectively. Adh1 levels served as loading controls. 
 
 
 
Supplementary Figure 3 | Phos-tag phosphate affinity gel electrophoresis analysis of genomically myc13-
tagged Sic1 or Sic1
T173A
. Sic1-myc13 or Sic1
T173A
-myc13 were analyzed by phos-tag phosphate affinity and SDS 
gel electrophoresis (followed by immunoblot analysis using anti-myc or anti-Sic1-pThr
173
 antibodies) in extracts 
from exponentially growing (0 h) and rapamycin-treated (RAP; 2 h) WT and cdc55∆ strains. The 6 
differentially phosphorylated Sic1-myc13 isoforms are numbered sequentially from 1 to 6 (right side of the 
panels). Adh1 levels served as loading controls. 
  
 
Supplementary Figure 4 | The Sic1
T173A
 allele compromises G1 arrest in rapamycin-treated cells. (a) FACS 
analyses were performed in exponentially growing (0 h) and rapamycin-treated (times indicated) WT, sic1
T173A
, 
sic1
S191A
, and sic1
T173A/S191A
 cells. The experiments were performed independently 3 times for each strain (one 
representative FACS profile is shown in Fig. 2g) and the quantifications (means ± SD) of the percentage of G1 
cells in the respective populations are presented. (b) Bar graphs show the percentage of G1 cells in the 
populations of rapamycin-treated (4 h) strains with the indicated genotypes with error bars indicating the 95% 
confidence interval. The data points from the 4-h rapamycin treatment were further used to perform an ANOVA 
analysis, which was followed by a Tukey's post-hoc test to examine the differences for each pair of strains. We 
found a highly significant difference among the four strains (ANOVA, p-value <0.001). Tukey's post-hoc test 
indicated that the values for WT and sic1
S191A
 cells were not significantly different from each other (p-
value=0.133); similarly the values for sic1
T173A
 and sic1
T173A/S191A
cells were also not significantly different from 
each other (p-value=0.97). All other pairwise comparisons were statistically significant (all p-values <0.001), 
showing that the values for WT and sic1
S191A
 cells significantly diverged from the ones of the sic1
T173A
 and 
sic1
T173A/S191A
 cells. 
 
 
 
Supplementary Figure 5 | Inactivation of the SCF
Cdc4
 ubiquitin ligase suppresses the defect in Sic1 
accumulation, but not in Sic1-Thr
173
 phosphorylation, in rapamycin-treated rim15∆ cdc4-2ts and igo1∆ 
igo2∆ cdc4-2tsmutant cells. (a) Sic1 levels and phosphorylation of Thr173 in Sic1 (Sic1-pThr173) were 
determined by immunoblot analyses using polyclonal anti-Sic1 and phosphospecific anti-Sic1-pThr
173
 
antibodies, respectively. Cells (genotypes indicated) were pre-grown exponentially at 24°C (0 h) and then 
shifted to 37°C for 1 or 2 h (to inactivate Cdc4-2
ts
) in the presence of rapamycin (RAP). Adh1 levels served as 
loading controls. The experiment was performed independently 3 times and one representative set of blots is 
shown. (b) Bars represent the ratio between the mean Sic1-pThr
173 
levels and Sic1 protein levels (± SD; 3 
independent experiments), determined in rapamycin-treated (2h at 37°C) cdc4-2
ts
, rim15∆ cdc4-2ts, and igo1∆ 
igo2∆ cdc4-2ts cells and expressed relative to the value in cdc4-2ts cells (set to 1.0). 
  
 
Supplementary Figure 6 | Loss of Mpk1, but not of Hog1, compromises timely G1 arrest in rapamycin-
treated cells. (a) FACS analyses were performed in exponentially growing (time 0 h) and rapamycin-treated 
(times indicated) WT, hog1∆, and mpk1∆ cells. FACS and BI analyses were performed as in Fig. 1a. The 
experiments were performed independently 3 times for each strain (one representative FACS profile is shown). 
(b) Quantifications (means ± SD) of the percentage of G1 cells in the respective populations in (a) are presented. 
(c) Bar graphs showing the percentage of G1 cells in the populations of rapamycin-treated (4 h) strains with the 
indicated genotypes with error bars indicating the 95% confidence interval. The data points from the 4-h 
rapamycin treatment were further used to perform an ANOVA analysis, which was followed by a Tukey's post-
hoc test to examine the differences for each pair of strains. We found a highly significant difference among the 
three strains (ANOVA, p-value <0.001). Tukey's post-hoc test indicated that the values for WT and hog1∆ cells 
were not significantly different from each other (p-value=0.53), but that the values for the mpk1∆ cells were 
significantly different from the other two strains (both p-values <0.002). 
  
Supplementary Figures 7-25: Original Blots 
 
 
 
 
Supplementary Figure 7 | Full-sized scans of Northern blots in Figure 1e. 
 
 
 
 
 
Supplementary Figure 8 | Full-sized scans of Western blots in Figure 1f. 
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Supplementary Figure 9 | Full-sized scans of Western blots in Figure 2a. 
 
 
 
Supplementary Figure 10 | Full-sized scans of Western blots in Figure 2c. 
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Supplementary Figure 11 |Full-sized scans of Western blots in Figure 2d. 
 
 
 
 
Supplementary Figure 12 | Full-sized scans of Western blots in Figure 2e.  
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Supplementary Figure 13 | Full-sized scans of Western blots in Figure 2f. 
 
 
 
Supplementary Figure 14 | Full-sized scans of Western blots in Figure 3a. 
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Supplementary Figure 15 | Full-sized scans of Western blots in Figure 3c. 
 
 
 
 
 
Supplementary Figure 16 | Full-sized scans of Western blots in Figure 4a. 
 
 
 
 
Supplementary Figure 17 | Full-sized scans of Western blots in Figure 4b. 
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Supplementary Figure 18 | Full-sized scans of Western blots in Figure 4c. 
 
 
 
 
Supplementary Figure 19 | Full-sized scans of Western blots in Figure 4d. 
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Supplementary Figure 20 | Full-sized scans of Western blots in Figure 4e. 
 
 
 
 
Supplementary Figure 21 | Full-sized scans of Western blots in Figure 5a. 
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Supplementary Figure 22 | Full-sized scans of Western blots in Supplementary Figure 1. 
 
 
 
Supplementary Figure 23 | Full-sized scans of Western blots in Supplementary Figure 2. 
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Supplementary Figure 24 | Full-sized scans of Western blots in Supplementary Figure 3. 
 
 
 
Supplementary Figure 25 | Full-sized scans of Western blots in Supplementary Figure 5. 
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Supplementary Tables 
 
Supplementary Table 1 | Strains Used in This Study. 
Strain Genotype Source Figure 
BY4741 MATa; his3∆1, leu2∆0, met15∆0, ura3∆0 reference1 1a, S1 
W303-1A MATa; ade2-1, trp1-1, can1-100, leu2-3,112, his3-11,15, ura3-1  1a, S1 
SP1 MATa; leu2, his3, trp1, ade8, ura3, can1 reference2 1a, S1 
JK9-3D MATa; leu2, his4, trp1, ura3, rme1, GAL,HMLa reference3 1b,1d-f,1i, 2a-b, 2f-g, 
S2, S4, S6 
YMM203 [SP1] rim15∆::kanMX this study S1 
YSB147 [BY4741] rim15∆::natMX, MET15 reference5 S1 
CDV95-4A [W303-1A] rim15∆::kanMX this study S1 
IP11 [JK9-3D]rim15∆::kanMX reference4 1c-f, 1i, 2a, S2 
YMM57-2A [JK9-3D] igo1∆::natMX, igo2∆::Hph-NT1 this study 1c-f, 1i, 2a 
YMM59 [JK9-3D] CLN1-myc13::kanMX this study 1f-g 
YMM60 [JK9-3D]CLN2-myc13::kanMX this study 1f-g 
YMM61 [JK9-3D] CLN3-myc13::kanMX this study 1f, 1h 
YMM87-2D [JK9-3D] rim15∆::kanMX, CLN1-myc13::kanMX this study 1f-g 
YMM88-12B [JK9-3D] rim15∆::kanMX, CLN2-myc13::kanMX this study 1f-g 
YMM78-2A [JK9-3D] rim15∆::kanMX, CLN3-myc13::kanMX this study 1f, 1h 
YMM85-5D [JK9-3D] igo1∆::natMX, igo2∆::Hph-NT1, CLN1-myc13::kanMX this study 1f-g 
YMM79-9A [JK9-3D] igo1∆::natMX, igo2∆::Hph-NT1, CLN2-myc13::kanMX this study 1f-g 
YMM80-5C [JK9-3D] igo1∆::natMX, igo2∆::Hph-NT1, CLN3-myc13::kanMX this study 1f, 1h 
YMM55-1C [JK9-3D] rim15∆::kanMX, cdc55∆::natMX this study 2a 
YMM90-3D [JK9-3D] igo1∆::natMX, igo2∆::Hph-NT1, cdc55∆::natMX this study 2a 
YMM46 [JK9-3D] cdc55∆::natMX this study 2a, 5a 
YMM98 [JK9-3D] sic1T173A-myc13::kanMX, EMP46::natMX this study 2c-e, S3 
YMM143-2A [JK9-3D] sic1T173A-myc13::kanMX,cdc55∆::natMXEMP46::natMX this study S3 
YMM63 [JK9-3D] SIC1-myc13::kanMX this study 2c-e, S3 
YMM68-9D [JK9-3D] rim15Δ::kanMX, SIC1-myc13::kanMX this study 2c-d 
YMM70-6B [JK9-3D] igo1Δ::natMX, igo2Δ::Hph-NT1, SIC1-myc13::kanMX this study 2c-d 
YMM69-1C [JK9-3D] cdc55Δ::natMX, SIC1-myc13::kanMX this study 2c-d, S3 
YMM100-9D [JK9-3D] rim15∆::kanMX, cdc55∆::natMX, SIC1-myc13::kanMX this study 2c-d 
YMM96 [JK9-3D] igo1∆::natMX, igo2∆::Hph-NT1, cdc55∆::natMX, 
SIC1-myc13::kanMX  
this study 2c-d 
YMM91 [JK9-3D] sic1T173A, EMP46::natMX this study 2f-g, S2, S4 
YMM101 [JK9-3D] sic1S191A, EMP46::natMX this study 2f-g, S4 
YMM103 [JK9-3D] sic1T173A/S191A, EMP46::natMX this study 2f-g, S4 
YMM105 [JK9-3D] sic1S191A-myc13::kanMX, EMP46::natMX this study 2e 
YMM133 [JK9-3D] sic1T173A/S191A-myc13::kanMX, EMP46::natMX this study 2e 
YMM114 [JK9-3D] cdc4-2::kanMX this study 3a-b, S5 
YMM117-3A [JK9-3D] rim15∆::kanMX, cdc4-2::kanMX this study 3a-b, S5 
YMM116-4A [JK9-3D] igo1∆::natMX, igo2∆::Hph-NT1, cdc4-2::kanMX this study 3a-b, S5 
YMM118-2D [JK9-3D] sic1T173A, EMP46::natMX, cdc4-2::kanMX this study 3a-b 
YMM77 [JK9-3D] SIC1-GFP(S65T)::kanMX this study 3c-d 
YMM97-7B [JK9-3D] rim15Δ::kanMX, SIC1-GFP(S65T)::kanMX this study 3c 
YMM99 [JK9-3D] sic1T173A-GFP(S65T)::kanMX this study 3c-d 
YMM67-1C [JK9-3D] sic1Δ::kanMX this study 2a 
YMM53 [JK9-3D] mpk1Δ::kanMX this study 4c-f, S6 
YMM65-2D [JK9-3D] mpk1Δ::kanMX, SIC1-myc13::kanMX this study 4a-b 
YMM204-14C [JK9-3D] hog1Δ::kanMX, SIC1-myc13::kanMX this study  4a-b 
YMM64-3C [JK9-3D] rim15Δ::kanMX, mpk1Δ::kanMX this study 4f 
YMM111-2A [JK9-3D] igo1∆::natMX, igo2∆::Hph-NT1, mpk1∆::kanMX this study 4f 
YMM130 [JK9-3D] hog1∆::kanMX this study S6 
 
  
Supplementary Table 2 | Plasmids Used in This Study. 
Plasmid Genotype Source Figure 
pRS416 CEN/ARS, URA3 reference
1
 1b 
pMM5 [pRS416] RME1 this study 1b 
p1308 
p1309 
p1310 
pMM10 
pSB004 
[pRS414] 
[pRS415] 
[pRS416] 
[pRS415]HIS4 
[pRS416] ADH1p-CDC55 
reference
1
 
reference
1
 
reference
1
 
this study 
reference
5
 
1d, 2d 
1d, 2d 
1d, 2d 
1d, 2d 
2a-b 
p834 
pMM6 
[pRS416] ADH1p 
[pRS416]MPK1-HA3 
reference
6
 
this study 
2a-b 
4c-e 
pMM7 [pRS416]mpk1
K54R
-HA3 this study 4c 
pMM8 pGEX-SIC1 this study 4c-d, 5a 
pMM9 pGEX-sic1
T173A
 this study 4c 
pMJA2610 [pRS416]CDC55-HA3 this study 5a 
pCDV487 pHAC195-GAL1-GST-RIM15, 2 µ,URA3 reference
4
 5a 
pLC1092 pGEX-IGO1 reference
7
 5a 
pLC1134 pGEX-igo1
S64A
 reference
7
 5a 
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